Bristol-Myers Squibb Company and Catalent, Inc. today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.

IVERIC bio, Inc. and Catalent Biologics, today announced that they have entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus vector for IVERIC bio’s gene therapy product candidates…

Catalent is to launch its new OneBio Suite^SM for the integrated development, manufacturing, and clinical supply of biologic drugs at the BIO International Convention

Catalent, Inc. (NYSE: CTLT) today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies.

Catalent, Inc. (NYSE: CTLT) and Paragon Bioservices, Inc. today announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.

Triphase Accelerator Corporation and Catalent today announced that Triphase Accelerator’s TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma, has been dosed in the first patient in a Phase 1 clinical trial.

Catalent Pharma Solutions today announced that two of its manufacturing experts will present at the INTERPHEX Conference and Exhibition, taking place at the Javits Center, New York City, on April 2-4, 2019.

The Catalent Applied Drug Delivery Institute today announced that it is to hold a one-day symposium entitled “Advances in Biologics Development and Delivery”.

Catalent Pharma Solutions today announced that two of its scientific experts will present at the International Society for Pharmaceutical Engineering (ISPE) Aseptic Conference.